Skip to main content
$367.06 +3.24 (+0.89%) At close · Aug 6
Market Cap
$44.09B
Shares
120.06M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$363.82 Open$362.80 Day$353.69–367.92 52W$161.90–428.88 Avg vol 30d1.5M Short int4.3M · 3.5% float · 3.2d Short vol49% Last earningsNov 6, 2026 DataJan 2020–Aug 2026 Filing10-Q · Jul 29

Up next

Next earnings call
Nov 6, 2026 Scheduled · in 13 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
filed Jul 29, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Neutral
      SellHoldBuy
      Technical Neutral Momentum Strong Sentiment Neutral Fundamentals Fair Quant / Vol Very High
      Market backdrop VIX 15.2 · calm Equity put/call 0.60
      Technical
      price trend
      Neutral
      50 / 200-day cross No cross
      Price vs 200-day avg +36%
      above
      Price vs 50-day avg −2%
      below
      RSI (14) 43
      neutral
      MACD trend Negative
      52-week position 76%
      mid-range
      Momentum
      relative strength
      Strong
      1-month return −8%
      trailing
      6-month return +109%
      trailing
      YTD return +43%
      this year
      Relative strength +98%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $371 › 200d $267 — 50d above 200d
      Institutional flow Distributing
      443 of 787 funds reported for Jun 30 · net -1.2M sh shares · +120 new
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      3.54% of float · ▼ -1.7% MoM · 3.2 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr low
      787 holders — near 3-yr low, contrarian setup
      Squeeze score 55
      elevated · 0–100
      Fundamentals
      Fair
      Revenue growth +10%
      Y/Y
      EPS growth −1%
      Y/Y
      Free cash flow $375.0M
      Valuation P/E 39.2
      rich
      Buyback $2.7B
      remaining
      Balance sheet $8.2B
      net debt
      Quant / Vol
      risk profile
      Very High
      Volatility 48%
      annualized · 1-yr
      Max drawdown −47%
      past year
      ATR 4.2%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Beat or met 0 of last 2
      Latest guidance · from the 8-K filed Jul 29, 2026
      GAAP · FY 2026 Initiated at least $6.52
      prior FY $9.84 midpoint −33.7% Y/Y
      Adjusted (non-GAAP) · FY 2026 Initiated at least $9.00
      Individual Medicare Advantage (MA) membership growth · FY 2026 Initiated 25%
      Insurance segment benefit ratio · FY 2026 Maintained 92.5% – 93%
      Guided vs delivered · last 2 settled
      EPS full year 2025
      guided $1700000000.00
      $9.84 Miss −100.0%
      EPS full year 2024
      guided $16.00
      $9.98 Miss −37.6%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Neutral
      1 · 4 · 1
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +36% Bullish
      Price vs 50-day avg
      −2% Neutral
      RSI (14)
      43 Neutral
      MACD trend
      Negative Bearish
      52-week position
      76% Neutral
      Market signals — smart money & positioning
      Mixed
      Trend (MA cross) No cross
      50d $371 › 200d $267 — 50d above 200d
      Institutional flow Distributing
      443 of 787 funds reported for Jun 30 · net -1.2M sh shares · +120 new
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Falling
      3.54% of float · ▼ -1.7% MoM · 3.2 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr low
      787 holders — near 3-yr low, contrarian setup
      Price context
      position in its 52-week range
      52-wk low $162 Now $364 · 76% 52-wk high $429
      vs 200-day avg +36% vs 50-day avg -2%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from its earnings releases, calls, and filings
      Metric Latest Period YoY
      CenterWell Senior Primary Care MaxHealth acquired centers 54 1Q26
      CenterWell Senior Primary Care MaxHealth acquired patients 59,000 1Q26
      CenterWell Senior Primary Care patient growth 110,500 1Q26
      State-based contracts membership growth 50,000 1Q26
      Consolidated Adjusted (non-GAAP) benefit ratio non-GAAP 90.2% FY 2025
      Consolidated Adjusted (non-GAAP) operating cost ratio non-GAAP 11.5% FY 2025
      Insurance segment Adjusted (non-GAAP) benefit ratio non-GAAP 90.4% FY 2025

      Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

      Versus peers

      Healthcare Plans — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      HUM
      Humana Inc
      this stock
      $44.09B +43.1% +10.1% 39.2 3.5%
      UNH
      Unitedhealth Group Inc
      $374.84B +26.7% +11.8% 31.1 1.9%
      CVS
      CVS HEALTH Corp
      $123.06B +27.8% +10.9% 25.4 1.5%
      ELV
      Elevance Health, Inc.
      $84.88B +12.8% +9.4% 17.3 2.8%
      CI
      Cigna Group
      $72.73B -0.6% +11.2% 11.4 2.3%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      878
      % held
      96.5%
      Reported
      443 of 787
      Top holder
      Dodge & Cox
      Held Float
      View
      Held by Funds
      Fund positions
      767
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      4.3M
      Days to cover
      3.2d
      Change
      -75.6K sh
      View
      Short Volume
      Short vol %
      49%
      As of
      Aug 6, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      13
      Value
      $5.2K
      As of
      Jul 10, 2026
      View
      Off-Exchange
      Off-exchange %
      45.8%
      Week of
      Jul 6, 2026
      Off-exch Lit
      View
      Smart Money
      Congressional Trades Buy
      Member
      Alan Armstrong
      Amount
      $1.0K–$15.0K
      Traded
      Mar 27, 2026
      View
      Financials
      Financials
      Revenue (FY)
      $129.7B
      Net income (FY)
      $1.2B
      EPS diluted
      $9.84
      View
      Buybacks
      Authorized
      $3.0B
      Remaining
      $2.7B
      Spent Remaining
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Jul 29, 2026
      This year
      14
      View
      Proposed Sales
      Value
      $2.7M
      Shares
      11.0K
      Filed
      Apr 8, 2025
      View
      Earnings & Events
      Earnings Calls Upcoming
      Next call
      Nov 6, 2026
      Last call
      Jul 29, 2026
      View
      Investor Relations
      Upcoming events
      2
      View

      Performance

      5D 20D 120D MTD YTD
      HUM -0.4% -8.2% +109.0% 0.0% +43.1%
      SPY +5.5% +3.3% +11.3% +3.1% +12.9%
      vs SPY -6.0% -11.5% +97.7% -3.1% +30.2%

      Capital returns

      Latest dividend
      $0.885 / share · ex Jun 26, 2026
      Raised 12.3%
      Paid (TTM)
      $3.54 / share · 4 payouts
      Dividend yield (TTM, derived)
      0.97%
      Buyback program · as of Jul 28, 2026
      Authorized
      $3.00B
      Spent (derived)
      $300.00M
      Remaining
      $2.70B
      Spent Remaining

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 49071 CUSIP 444859102 13F (30d) 422 filings 395 filers Visit website Investor relations